Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| HSBC Holdings | 0.88% | $3.35M | $230.69B | 48.77% | 78 Outperform | |
| Novartis | 0.83% | $3.15M | $249.53B | 16.84% | 78 Outperform | |
| SoftBank Group | 0.81% | $3.07M | $229.24B | 186.30% | 63 Neutral | |
| ASML Holding | 0.76% | $2.89M | $398.35B | 47.17% | 81 Outperform | |
| Roche Holding AG | 0.76% | $2.89M | CHF217.35B | 4.21% | 73 Outperform | |
| Royal Bank Of Canada | 0.70% | $2.66M | $207.80B | 19.15% | 75 Outperform | |
| SAFRAN SA | 0.67% | $2.56M | €126.90B | 43.71% | 67 Neutral | |
| Vinci SA | 0.67% | $2.55M | €67.77B | 16.94% | 75 Outperform | |
| Celestica | 0.65% | $2.49M | $34.17B | 366.62% | 76 Outperform | |
| Sony Group | 0.65% | $2.49M | $175.52B | 61.69% | 78 Outperform |